Aplagon

Description

Aplagon develops first-in-class therapeutics for thromboinflammatory diseases, focusing on clinical-stage drug APAC to treat thrombotic and vascular occlusion–related cardiovascular conditions.

Related

• Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs for retinal vascular diseases, focusing on diabetic retinopathy and…
• AortyxAortyx develops a biomimetic, bioresorbable endovascular patch and a dual-steerable catheter system to treat aortic dissection, for use by…
• NanoPhoriaNanoPhoria develops inhalable Nano-in-Micro delivery formulations to enable tissue-directed delivery of therapeutic peptides and RNAs for…
• RobeautéRobeauté builds a microrobotic platform to navigate, diagnose and treat neurological conditions, developing rice-sized robots and surgical…
• Ysios CapitalYsios Capital invests in biotech ventures, building portfolios of innovative therapeutic drug companies and supporting development of…
• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics modulating the Wiskott–Aldrich Syndrome protein for oncology and…
• Ionis Pharmaceuticals ($IONS)Ionis Pharmaceuticals develops RNA- and DNA-targeted therapeutics, designing antisense and related nucleic acid medicines to treat serious…
• ThelperThelper develops first-in-class antiviral antibody drug conjugates (ADCs) targeting virally encoded biomarkers in aggressive solid tumors…
• Cartesian Therapeutics ($RNAC)Cartesian Therapeutics develops clinical-stage mRNA cell therapies designed to treat autoimmune diseases, aiming to expand access to cell…
• Max-Planck-Institut für molekulare BiomedizinMax-Planck-Institut für molekulare Biomedizin conducts basic cell and vascular biology research, develops genetic technologies and…
• Merck Cambridge Discovery ($MRK)Merck Cambridge Discovery develops medicines and vaccines through research, clinical trials, and publications, focusing on diseases…
• Verve TherapeuticsSingle-course gene-editing therapies for cardiovascular disease. Cambridge MA; CRISPR-based PCSK9 + ANGPTL3 programs.